Delving into the Latest Updates on Taizhou Maibotaike Biotechnology Co., Ltd. with Synapse

Overview

Primary objective: To compare the similarity of pharmacokinetic (PK) characteristics of CMAB819 and Opdivo® in the treatment of recurrent or metastatic head and neck squamous cell carcinoma. Secondary objective: To compare the safety, immunogenicity and preliminary efficacy of CMAB819 and Opdivo® in the treatment of recurrent or metastatic head and neck squamous cell carcinoma.

Start Date24 Sep 2020

Sponsor / Collaborator

Taizhou Maibotaike Biotechnology Co., Ltd.

[+1]

100 Clinical Results associated with Taizhou Maibotaike Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Taizhou Maibotaike Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Taizhou Maibotaike Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Taizhou Maibotaike Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 29 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data